Literature DB >> 26349419

Neuroblastoma.

Johannes Hubertus Schulte1, Angelika Eggert1.   

Abstract

Neuroblastoma is the most common extracranial solid tumor in children. Since its first description some 150 years ago, its enigmatic clinical presentation has challenged clinicians and fascinated basic researchers. This article presents an overview of the key clinical features of neuroblastoma and current therapeutic approaches. It also highlights how our understanding of sympathoadrenal developmental biology, coupled with transcriptome analyses, next-generation sequencing, and genome-wide association and epigenetic studies, has illuminated critical signal transduction pathways involved in neuroblastoma tumorigenesis and identified therapeutically tractable targets for clinical development.

Entities:  

Mesh:

Year:  2015        PMID: 26349419     DOI: 10.1615/critrevoncog.2015014033

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  14 in total

1.  Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.

Authors:  Veronica Veschi; Zhihui Liu; Ty C Voss; Laurent Ozbun; Berkley Gryder; Chunhua Yan; Ying Hu; Anqi Ma; Jian Jin; Sharlyn J Mazur; Norris Lam; Barbara K Souza; Giuseppe Giannini; Gordon L Hager; Cheryl H Arrowsmith; Javed Khan; Ettore Appella; Carol J Thiele
Journal:  Cancer Cell       Date:  2017-01-09       Impact factor: 31.743

2.  Clinical characteristics of adrenal tumors in children: a retrospective review of a 15-year single-center experience.

Authors:  Xiaokun Lin; Dazhou Wu; Congde Chen; Na Zheng
Journal:  Int Urol Nephrol       Date:  2016-12-17       Impact factor: 2.370

3.  Targeting the Chromosomal Passenger Complex Subunit INCENP Induces Polyploidization, Apoptosis, and Senescence in Neuroblastoma.

Authors:  Ming Sun; Veronica Veschi; Sukriti Bagchi; Man Xu; Arnulfo Mendoza; Zhihui Liu; Carol J Thiele
Journal:  Cancer Res       Date:  2019-08-15       Impact factor: 12.701

4.  A Case Series of Pediatric Intestinal Ganglioneuromatosis With Novel Phenotypic and Genotypic Profile.

Authors:  Yuan Fang; Ye Zhang; Rui Dong; Yi-Zhen Wang; Lian Chen; Gong Chen
Journal:  Front Med (Lausanne)       Date:  2022-06-16

5.  A comprehensive characterization of rare mitochondrial DNA variants in neuroblastoma.

Authors:  Francesco Maria Calabrese; Rosanna Clima; Piero Pignataro; Vito Alessandro Lasorsa; Michael D Hogarty; Aurora Castellano; Massimo Conte; Gian Paolo Tonini; Achille Iolascon; Giuseppe Gasparre; Mario Capasso
Journal:  Oncotarget       Date:  2016-08-02

6.  Promoter hypermethylation as a mechanism for Lamin A/C silencing in a subset of neuroblastoma cells.

Authors:  Ines Rauschert; Fabian Aldunate; Jens Preussner; Miguel Arocena-Sutz; Vanina Peraza; Mario Looso; Juan C Benech; Ruben Agrelo
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

7.  ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid.

Authors:  Ji-Cheng Wu; Hua-Mao Jiang; Xiang-Hong Yang; Hua-Chuan Zheng
Journal:  Cancer Med       Date:  2018-08-09       Impact factor: 4.452

8.  Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma.

Authors:  Marco Lodrini; Annika Sprüssel; Kathy Astrahantseff; Daniela Tiburtius; Robert Konschak; Holger N Lode; Matthias Fischer; Ulrich Keilholz; Angelika Eggert; Hedwig E Deubzer
Journal:  Oncotarget       Date:  2017-07-07

9.  Serum Interleukin-6 Level and the rs1800795 Polymorphism in its Gene Associated with Neuroblastoma Risk in Chinese Children.

Authors:  Qian Zhao; Mei Jin; Da-Wei Zhang; Wen Zhao; Xi-Si Wang; Zhi-Xia Yue; Chao Duan; Cheng Huang; Xiao-Li Ma
Journal:  Chin Med J (Engl)       Date:  2018-05-05       Impact factor: 2.628

10.  A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma.

Authors:  Meike Vogler; Simone Fulda; Annika Bierbrauer; Maureen Jacob
Journal:  Br J Cancer       Date:  2020-03-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.